-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Neutral on Aldeyra Therapeutics, Maintains $2 Price Target

Benzinga·09/30/2026 10:14:29
Listen to the news
HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Neutral and maintains $2 price target.